Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;36(2):341-352.
doi: 10.1016/j.hoc.2021.11.001. Epub 2022 Mar 11.

Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia

Morie A Gertz  1
Affiliations
Review

Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia

Morie A Gertz. Hematol Oncol Clin North Am. 2022 Apr.

Abstract

Cold agglutinin disease represents a form of immune-mediated hemolytic anemia whereby an IgM protein either monoclonal or polyclonal deposits complement on the surface of the red blood cell. Once complement is deposited, the 3rd component of complement is recognized by receptors in the mononuclear phagocyte system resulting in spherocytic extravascular hemolysis. This results in a Coombs positive hemolytic anemia with the peripheral blood film showing agglutination. In many instances, the source is a clonal population of lymphoplasmacytic cells in the bone marrow producing a monoclonal IgM protein. Traditional and emerging therapies directed against the production of the IgM may have a positive effect on hemolytic anemia. Success in the management of cold agglutinin disease with rituximab, fludarabine, bortezomib, and bendamustine has all been reported. Recent studies have demonstrated that the blockade of complement with sutimlimab can stop the hemolysis without the use of systemic chemotherapy.

Keywords: Cold agglutinin disease; IgM monoclonal gammopathy; Immune-mediated hemolysis; Waldenström macroglobulinemia.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

Honorarium from Sanofi.

There are currently no FDA-approved therapies for cold agglutinin hemolytic anemia. All medications mentioned are all off-label.

Figures

Fig. 1.
Fig. 1.
Pathophysiology of cold agglutinin in disease.
Fig. 2.
Fig. 2.
Peripheral blood film showing agglutination.
Fig. 3.
Fig. 3.
Livedo reticularis of the hands.
Fig. 4.
Fig. 4.
Livedo reticularis of the lower extremities.
See this image and copyright information in PMC

References

    1. Das SS, Bhattacharya S, Bhartia S. Clinical and serological characterization of cold agglutinin syndrome in a Tertiary Care Hospital in Eastern India. Asian J Transfus Sci 2015;9(2):173–6. - PMC - PubMed
    1. Cermak J, Pisacka M. Autoimmune hemolytic anemia. Vnitr Lek 2018;64(5): 514–9. - PubMed
    1. Berentsen S New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia. Front Immunol 2020;11:590. - PMC - PubMed
    1. Bass GF, Tuscano ET, Tuscano JM. Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev 2014;13(4–5):560–4. - PubMed
    1. Akpoguma AO, Carlisle TL, Lentz SR. Case report: paroxysmal cold hemoglobinuria presenting during pregnancy. BMC Hematol 2015;15(1):3. - PMC - PubMed

Publication types